Please Wait
Applying Filters...
menu
    • menu
    TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.

    Virtual Booth

    Contact Supplier

    Your reliable CDMO partner - agile, scalable, top-quality Small Molecule API & HPAPI solutions from concept to market

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-11-24

    Virtual Booth

    An Enquiry

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Ropeginterferon ALFA-2B

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    PharmaEssentia's Phase 3 SURPASS-ET Trial Published in The Lancet
    PharmaEssentia's Phase 3 SURPASS-ET Trial Published in The Lancet

    24 Nov 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251124044530/en/PharmaEssentia-Announces-Publication-of-Phase-3-SURPASS-ET-Results-in-The-Lancet-Haematology

    BUSINESSWIRE
    24 Nov 2025
    Share Share
    PharmaEssentia Announces Presentations At ASH 2025
    PharmaEssentia Announces Presentations At ASH 2025

    18 Nov 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251118122426/en/PharmaEssentia-Announces-Presentations-at-ASH-2025

    BUSINESSWIRE
    18 Nov 2025
    Share Share
    Pint Pharma Gets ANVISA Nod For Besremi In Polycythemia Vera
    Pint Pharma Gets ANVISA Nod For Besremi In Polycythemia Vera

    20 Mar 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250320323757/en/Pint-Pharma-Announces-ANVISAs-Approval-of-BESREMi-ropeginterferon-alfa-2b-for-the-Treatment-of-Polycythemia-Vera

    BUSINESSWIRE
    20 Mar 2025
    Share Share
    PharmaEssentia Highlights Bersremi Availability Amid Pegasys Shortage
    PharmaEssentia Highlights Bersremi Availability Amid Pegasys Shortage

    04 Mar 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250304127897/en

    BUSINESSWIRE
    04 Mar 2025
    Share Share
    Clinical Review of Pegylated Interferons Suggests Formulation
    Clinical Review of Pegylated Interferons Suggests Formulation

    21 Feb 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240221809028/en

    BUSINESSWIRE
    21 Feb 2024
    Share Share
    Presentations at MPN Congress Reinforce Role of ropeginterferon alfa-2b-njft
    Presentations at MPN Congress Reinforce Role of ropeginterferon alfa-2b-njft

    02 Nov 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20231102403190/en

    BUSINESSWIRE
    02 Nov 2023
    Share Share